Synopsis
Synopsis
0
USDMF
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
API
0
FDF
0
FDA Orange Book
0
Canada
0
Australia
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
1. 4-phenoxy-3-pyrrolidin-1-yl-5-sulfamoylbenzoic Acid
2. Hoe 118
1. 55837-27-9
2. Tauliz
3. 4-phenoxy-3-pyrrolidin-1-yl-5-sulfamoylbenzoic Acid
4. Eurelix
5. Hoe 118
6. 4-phenoxy-3-(pyrrolidin-1-yl)-5-sulfamoylbenzoic Acid
7. Hoe-118
8. Benzoic Acid, 3-(aminosulfonyl)-4-phenoxy-5-(1-pyrrolidinyl)-
9. S 73 4118
10. 4-phenoxy-3-(1-pyrrolidinyl)-5-sulfamoylbenzoic Acid
11. Dq6kk6gv93
12. Ncgc00016878-01
13. Arlix
14. Cas-55837-27-9
15. Dsstox_cid_3488
16. Dsstox_rid_77050
17. Dsstox_gsid_23488
18. S-734118
19. S-73-4118
20. Piretanido [spanish]
21. Piretanido
22. Piretanidum
23. Piretanidum [inn-latin]
24. Piretanido [inn-spanish]
25. Arelix (tn)
26. Einecs 259-852-9
27. Unii-dq6kk6gv93
28. Brn 5633965
29. Piretanide [usan:inn:ban:jan]
30. Piretanide-[d4]
31. S 734118
32. 3-(aminosulfonyl)-4-phenoxy-5-(1-pyrrolidinyl)-benzoic Acid
33. Piretanide [mi]
34. Piretanide [inn]
35. Piretanide [jan]
36. Acide Phenoxy-4-(1-pyrrolidinyl)-3-sulfamoyl-5 Benzoique [french]
37. Prestwick0_001047
38. Prestwick1_001047
39. Prestwick2_001047
40. Prestwick3_001047
41. Piretanide [usan]
42. Piretanide [mart.]
43. Piretanide [who-dd]
44. Schembl49473
45. Bspbio_000974
46. Mls002154123
47. Piretanide (jan/usan/inn)
48. Spbio_002907
49. Bpbio1_001072
50. Chembl349803
51. Gtpl4742
52. Dtxsid2023488
53. Chebi:32015
54. Piretanide For System Suitability
55. Acide Phenoxy-4-(1-pyrrolidinyl)-3-sulfamoyl-5 Benzoique
56. Piretanide [ep Monograph]
57. Hms1571a16
58. Hms2098a16
59. Hms2230g15
60. Hms3372o22
61. Hms3715a16
62. Zinc3812930
63. Tox21_110661
64. Akos015895445
65. Tox21_110661_1
66. Ccg-221047
67. Db02925
68. Ncgc00016878-02
69. Ncgc00016878-04
70. Smr001233430
71. Hy-119816
72. Ab00514020
73. Cs-0078068
74. Ft-0673944
75. 2-methyl-2-propylpropane-1,3-diyl Dicarbamate
76. D01634
77. 837p279
78. A924106
79. Sr-01000838837
80. 4-phenoxy-3-(pyrrolidinyl)-5-sulfamoylbenzoic Acid
81. Q3905617
82. Sr-01000838837-2
83. W-105543
84. 3-(1-pyrrolidinyl)-4-phenoxy-5-sulphamylbenzoic Acid
85. Brd-k87990216-001-03-7
86. 4-phenoxy-3-(1-pyrrolidinyl)-5-sulphamoylbenzoic Acid
87. F2173-0688
88. 3-(aminosulfonyl)-4-(phenyloxy)-5-pyrrolidin-1-ylbenzoic Acid
Molecular Weight | 362.4 g/mol |
---|---|
Molecular Formula | C17H18N2O5S |
XLogP3 | 2.2 |
Hydrogen Bond Donor Count | 2 |
Hydrogen Bond Acceptor Count | 7 |
Rotatable Bond Count | 5 |
Exact Mass | 362.09364285 g/mol |
Monoisotopic Mass | 362.09364285 g/mol |
Topological Polar Surface Area | 118 Ų |
Heavy Atom Count | 25 |
Formal Charge | 0 |
Complexity | 564 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Diuretics
Agents that promote the excretion of urine through their effects on kidney function. (See all compounds classified as Diuretics.)
Sodium Potassium Chloride Symporter Inhibitors
Agents that inhibit SODIUM-POTASSIUM-CHLORIDE SYMPORTERS which are concentrated in the thick ascending limb at the junction of the LOOP OF HENLE and KIDNEY TUBULES, DISTAL. They act as DIURETICS. Excess use is associated with HYPOKALEMIA and HYPERGLYCEMIA. (See all compounds classified as Sodium Potassium Chloride Symporter Inhibitors.)
C - Cardiovascular system
C03 - Diuretics
C03C - High-ceiling diuretics
C03CA - Sulfonamides, plain
C03CA03 - Piretanide
Global Sales Information
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?